Androgens and insulin - Two key players in polycystic ovary syndrome: Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome

Gynakologisch-geburtshilfliche Rundschau

Volumn 48, Issue 1, 2008, Pages 9-15

  Schüring, Andreas N ^a   Schulte, Nicole ^a   Sonntag, Barbara ^a   Kiesel, Ludwig ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Androgens; Genetics; Insulin; Pathophysiology; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; INSULIN;

ANDROGEN METABOLISM; ARTICLE; CONSENSUS; FEMALE; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; MOLECULAR GENETICS; OVARY POLYCYSTIC DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; RISK FACTOR;

ANDROGENS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INSULIN; INSULIN RESISTANCE; MODELS, GENETIC; POLYCYSTIC OVARY SYNDROME;

EID: 38549123824     PISSN: 10188843     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111465     Document Type: Article

References (35)

1. Ehrmann DA: Polycystic ovary syndrome. N Engl J Med 2005;352:1223-1236.
2. Azziz R: Androgen excess is the key element in polycystic ovary syndrome. Fertil Steril 2003;80:252-254.
3. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
4. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774-800.
5. Essah PA, Nestler JE: The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006;29:270-280.
6. Futterweit W, Deligdisch L: Histopathological effects of exogenously administered testosterone in 19 female to male transsexuals. J Clin Endocrinol Metab 1986;62:16-21.
7. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D: Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod 2003;18:598-603.
8. Vendola K, Zhou J, Adesanya OO, Weil SJ, Bondy CA: Androgens stimulate early stages of follicular growth in the primate ovary. J Clin Invest 1998;101:2622-2629.
9. Agarwal SK, Judd HL, Magoffin DA: A mechanism for the suppression of estrogen production in polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81:3686-3691.
10. Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC: Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000;85:4047-4052.
11. Pastor CL, Griffin-Corff ML, Aloi JA, Evans WS, Marshall JC: Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 1998;83:582-590.
12. Apter D, Butzow T, Laughlin GA, Yen S: Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 1994;79:119-125.
13. Abbott DH, Padmanabhan V, Dumesic DA: Contributions of androgen and estrogen to fetal programming of ovarian dysfunction. Reprod Biol Endocrinol 2006;4:17.
14. Legro RS, Strauss JF: Molecular progress in infertility: polycystic ovary syndrome. Fertil Steril 2002;78:569-576.
15. Franks S, Gilling-Smith C, Gharani N, McCarthy M: Pathogenesis of polycystic ovary syndrome: evidence for a genetically determined disorder of ovarian androgen production. Hum Fertil 2000;3:77-79.
16. Rosenfield RL, Barnes RB, Cara JF, Lucky AW: Dysregulation of cytochrome P450c 17 alpha as the cause of polycystic ovarian syndrome. Fertil Steril 1990;53:785-791.
17. Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR: Microsatellite polymorphism (TTTTA)n at -528 base pairs of gene CYP11a influences hyperan drogenemia in patients with polycystic ovary syndrome. Fertil Steril 2000;73:735-741.
18. Urbanek M, Legro RS, Driscoll DA, Azziz R, Ehrmann DA, Norman RJ, Strauss JF, Spielman RS, Dunaif A: Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci USA 1999;96:8573-8578.
19. Gilling-Smith C, Willis DS, Beard RW, Franks S: Hypersecretion of androstendione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158-1165.
20. Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, McCarthy M, Franks S, Williamson R: Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet 1997;6:397-402.
21. Witchel SF, Aston CE: The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab 2000;13(suppl 5):1315-1317.
22. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I: Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab 2003;88:5976-5980.
23. Hickey T, Chandy A, Norman RJ: The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:161-165.
24. Schüring AN, Jürgens A, Gromoll J, Nieschlag E, Kiesel L: The CAG repeat polymorphism influences the phenotype of polycystic ovary syndrome (PCOS). J Soc Gynecol Invest 2006;13(suppl):269A.
25. Dunaif A, Segal KR, Futterweit W, Dobrjansky A: Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-1174.
26. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
27. Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER, Cooperative Multicenter Reproductive Medicine Network: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-566.
28. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003;24:302-312.
29. Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E: Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001;281:392-399.
30. Urbanek M, Woodroffe A, Ewens KG, Diamanti-Kandarakis E, Legro RS, Strauss JF 3rd, Dunaif A, Spielman RS: Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab 2005;90:6623-6629.
31. Elbers JM, Giltay EJ, Teerlink T, Scheffer PG, Asscheman H, Seidell JC, Gooren LJ: Effects of sex steroids on components of the insulin resistance syndrome in transsexual subjects. Clin Endocrinol (Oxf) 2003;58:562-571.
32. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-2556.
33. Escobar-Morreale HF, Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266-272.
34. Diamanti-Kandarakis E, Piperi C: Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Hum Reprod Update 2005;11:631-643.
35. Schüring AN, Sonntag B, Kiesel L: Androgene und Insulin in Pathophysiologie und Genetik des PCO-Syndroms. Gynäkologische Endokrinologie 2006;4:143-148.